Clinical Investigators Meeting
The Clinical Investigators Meeting (CIM) is the forum for faculty review of all new primary and secondary therapy protocols that are submitted to the Hematology Scientific Review Committee (SRC).
Studies Reviewed at CIM
CIM is required for all new primary and secondary therapy protocols reviewed by the Hematology SRC. Generally the CIM and SRC reviews are conducted sequentially, with the CIM review scheduled first.*
The two primary considerations for CIM review are:
- Does the study involve patients under the care of an SCCA outpatient or UWMC inpatient hematopoietic cell transplant team?
- Is the study investigator-initiated?
*For industry-sponsored clinical trials that do not involve patients under the care of an SCCA outpatient or UWMC inpatient hematopoietic cell transplant team, an informational presentation at CIM, scheduled in parallel with Hematology SRC review, is allowed instead of sequentially scheduled CIM prior to SRC review.
Focus of CIM Discussion
The discussion during the meeting focuses on:
- The scientific merit and the priority of the study in relation to others within the same disease
- Sample size
- Feasibility (both intramurally and extramurally)
- The coordinating site
At CIM, the protocol’s Principal Investigator (PI) or designee presents the new protocol to the faculty.
Sequentially reviewed protocols are assigned one CIM reviewer and one SRC reviewer. The written critiques of the CIM and SRC reviewers are discussed, modifications are proposed, and faculty input is obtained. A confidential vote of the faculty is taken at the close of the meeting. The ballot serves two purposes: The first is to recommend acceptance or rejection of the protocol. The second is to allow for a numeric scoring of the degree of enthusiasm for acceptance.
Parallel reviewed protocols are assigned only to an SRC reviewer. Informational presentations are followed by a brief discussion session for faculty input. No faculty vote is obtained.
Clinical Investigator Meetings are held every other Tuesday from 4:00 – 5:00 p.m. Protocols are automatically scheduled to the next open CIM and Hematology SRC meetings. Protocols are further prioritized by their submission date to Clinical Research Support and the availability of the Principal Investigator to present at CIM.
New Standard Treatment Protocols
New Standard Treatment Protocols are discussed at the CIM as determined by the Principal Investigator and/or meeting Chairs. Standard Treatment Protocols are not sent to SRC following CIM.
For meeting questions and/or upcoming available meeting dates. Contact CIM Coordinator, Leslie Woestenborg, via email or at 206-667-1165.